Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published October 23, 2014 | Supplemental Material + Published
Journal Article Open

Tumor Xenograft Uptake of a Pyrrole−Imidazole (Py-Im) Polyamide Varies as a Function of Cell Line Grafted

Abstract

Subcutaneous xenografts represent a popular approach to evaluate efficacy of prospective molecular therapeutics in vivo. In the present study, the C-14 labeled radioactive pyrrole–imidazole (Py-Im) polyamide 1, targeted to the 5′-WGWWCW-3′ DNA sequence, was evaluated with regard to its uptake properties in subcutaneous xenografts, derived from the human tumor cell lines LNCaP (prostate), A549 (lung), and U251 (brain), respectively. Significant variation in compound tumor concentrations was seen in xenografts derived from these three cell lines. Influence of cell line grafted on systemic polyamide elimination was established. With A549, a marked variation in localization of 1 was determined between Matrigel-negative and -positive xenografts. An extensive tissue distribution analysis of 1 in wild-type animals was conducted, enabling the comparison between the xenografts and the corresponding host organs of origin.

Additional Information

© 2014 American Chemical Society. ACS AuthorChoice - This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes. Received: June 26, 2014. Publication Date (Web): September 19, 2014. J.A.R. is grateful to the Alexander von Humboldt foundation for the award of a Feodor Lynen postdoctoral fellowship. We thank Bogdan Olenyuk for helpful discussions. The research presented has been supported by the National Institutes of Health (Grants GM51747 and GM27681). Author Contributions: The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. The authors declare no competing financial interest.

Attached Files

Published - jm500964c.pdf

Supplemental Material - jm500964c_si_001.pdf

Files

jm500964c.pdf
Files (1.3 MB)
Name Size Download all
md5:6940de2767c56c1797f5f14dd635bce3
690.1 kB Preview Download
md5:3d62117d36307f1325849de1adabb586
605.3 kB Preview Download

Additional details

Created:
August 20, 2023
Modified:
October 17, 2023